Investor Caligan Partners LP
Manager David Johnson
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Caligan Partners LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-08-14 13G EOLS / Evolus, Inc. 3,341,970
2025-05-14 13G YMAB / Y-mAbs Therapeutics, Inc. 2,342,609
2025-02-12 13G VRCA / Verrica Pharmaceuticals Inc. 15,856,653
2024-09-18 13D/A ALIM / Alimera Sciences, Inc. 17,635,154 0
2024-09-12 13D/A LQDA / Liquidia Corporation 6,994,997 8,118,592
2024-09-04 13D/A LQDA / Liquidia Corporation 10,360,945 6,994,997
2024-06-24 13D/A ALIM / Alimera Sciences, Inc. 17,635,154 17,635,154
2024-05-30 13D/A ANIK / Anika Therapeutics, Inc. 1,423,493 1,435,993
2024-03-06 13D/A ANIK / Anika Therapeutics, Inc. 1,081,360 1,423,493
2024-01-08 13D/A LAB / Standard BioTools Inc. 7,797,454 7,042,413
2023-12-14 13D/A LQDA / Liquidia Corporation 7,167,663 10,360,945
2023-09-11 13D/A ANIK / Anika Therapeutics, Inc. 902,086 1,081,360
2023-08-17 13D ANIK / Anika Therapeutics, Inc. 902,086
2023-08-03 13D/A ALIM / Alimera Sciences, Inc. 915,057,915,057 17,635,154
2023-07-03 13D/A LAB / Standard BioTools Inc. 8,576,799 7,797,454
2023-06-02 13D/A EXEL / Exelixis, Inc. 850,000 910,730
2023-05-18 13D/A ALIM / Alimera Sciences, Inc. 724,716 915,057,915,057
2023-03-28 13D/A ALIM / Alimera Sciences, Inc. 411,527 724,716
2023-03-27 13D/A EXEL / Exelixis, Inc. 850,000 850,000
2023-03-20 13D EXEL / Exelixis, Inc. 850,000
2022-12-30 13D/A LAB / Standard BioTools Inc. 11,444,836 8,576,799
2022-12-09 13D/A ADMA / ADMA Biologics, Inc. 10,893,237 10,264,311
2022-08-05 13D/A LAB / Standard BioTools Inc. 10,423,188 11,444,836
2022-06-07 13D/A LAB / Standard BioTools Inc. 9,484,838 10,423,188
2022-05-25 13D ALIM / Alimera Sciences, Inc. 411,527
2022-05-03 13D/A FLDM / Standard BioTools Inc 8,380,265 9,484,838
2022-03-29 13D/A FLDM / Standard BioTools Inc 8,380,265 8,380,265
2022-02-04 13D ADMA / ADMA Biologics, Inc. 10,893,237
2021-12-07 13D/A LQDA / Liquidia Corporation 8,328,418 7,167,663
2021-05-10 13D FLDM / Standard BioTools Inc 8,380,265
2021-04-15 13D LQDA / Liquidia Corporation 8,328,418
2020-11-16 13D/A US00163U1060 / AMAG Pharmaceuticals, Inc. 3,519,287 0
2019-10-10 13D/A US00163U1060 / AMAG Pharmaceuticals, Inc. 3,499,428 3,519,287
2019-09-30 13D/A KN / Knowles Corporation 4,621,578 4,316,236
2019-09-04 13D/A US00163U1060 / AMAG Pharmaceuticals, Inc. 3,499,428 3,499,428
2019-08-15 13D US00163U1060 / AMAG Pharmaceuticals, Inc. 3,499,428
2019-05-09 13D/A KN / Knowles Corporation 4,045,343 4,621,578
2019-03-11 13D KN / Knowles Corporation 4,045,343